[Kalpana]

Biocon Limited is an Indian Biopharmaceutical giant based in Bangalore. Its the biggest manufacturer of fermentation products in India and has a strong foothold in Mabs and chemical synthesis products too.

It started back in 1979, nearly two and a half decades ago, with its market in India, pan-Europe and USA for selling enzymes using solid substrate fermentation. After a huge success it started climbing the success stairs with submerged fermentation and mammalian cell culture products. It has received huge recognition in the market for its large scale fermentation manufacturing capacity and for its R&D's expertise on technical patents and for development of new challenging fermentation products (like statins, antibiotics, resin based fermentation, peptides, immuomodulators etc). It has tie-ups with biggest players of the biotechnology world and has been able to deliver best and affordable products to India and world. Apart from business company indulges in philanthropic and extra-curricular activities too.

Here you can find some recent developments and company vacancies (as mentioned in their job site).

• Biocon listed in Top 20 employers by Science Magazine-2012
  

Science Magazine conducts a worldwide annual survey for companies based on Six Key parameters:
- Innovative Leader in the Industry
- Treats Employees with Respect
- Is Socially Responsible
- Has Loyal Employees
- Does Important Quality Research
- Makes Changes Needed

Biocon was ranked in 19th position leaving around 25K companies behind. And its the only Asian company in the list.

• Biocon ready to launch Alzumab
  

Alzumab a novel monoclonal antibody based drug for treatment of Psoriasis is all set to launch this July. Psoriasis is an auto-immune skin disease which causes inflammation with its major symptoms being redness and burning. With current survey data around 2-3% of country's population is suffering from the same. There have been chemical treatment routes which are accompanied by side effects and unsatisfactory results. A biologic route (like using an antibody) is more safe and effective to bring a relief in the patients.

• Biocon to open a unit in Malaysia
  

Biocon the biggest manufacturer of Insulin in India is all set to enter Malaysia. It has planned to open a 40 acre facility at Bio-Xcell, Johor Malaysia. It will be a high end research and manufacturing facility to provide affordable diabetic drugs. This will create multiple opportunities for young bio-researchers of Asia.

For more news on Biocon click here.

• Current Vacancies
  

Following are vacancies for India and Bangalore R&D center of Biocon. Kindly see the list below and apply on the company website.

[Jessica]

June 21, 2013
Biopharma company Biocon is seeing increasing demand for its contract research services in allied areas such as agrochemicals, petrochemicals, and even electronics - into which it has recently expanded - as an offshoot of its core biopharmeceuticals and biologics research expertise.
(Financial Express)

--------------------------
July 27, 2013
Indian pharma market needs strong regulatory set-up: Kiran Mazumdar-Shaw
Biocon, which posted a net profit of 19% on Friday, is looking at gaining marketshare and improve its margins with greater focus on its product mixes and organisational efficiencies. Biocon chairman and managing director Kiran Mazumdar-Shaw, tells Ajay Sukumaran that the company has outpaced the market despite the challenges and that the pharmaceutical market needs to have a more robust regulatory set-up.
----------------------------------

Job Openings:
Senior Manager - Supply Chain Management, Bangalore
+
29 Other Jobs opportunities

See all job openings:
http://111.93.133.153/Candidate%20Portal...fault.aspx

--------------------------------


Photo: Kiran Mazumdar-Shaw

[priyasaravanan_1406]

Latest Drug launch by Biocon as a Solution to Psoriasis

Biocon on 10th August 2013 launched a new drug as a cure for Psoriasis.

Drug: ALZUMAb

Use: To treat Psoriasis

What is Psoriasis?

Psoriasis is a skin disease which is chronic in nature occurs as an over response of one’s own immune system against the skin cells.

Types of Psoriasis:

Plaque, Guttate, erythrodermic, pustular and inverse psoriasis
The drug ALZUMAb is effective against plaque Psoriasis

ALZUMAb

Humanized IgG1 Monoclonal antibody / anti- CD6 antibody

It is of biological origin

Target: CD6 Cells

Mode of Action: Attaches to CD6 cells and turns down T cell activation.

Salient Features of the drug

As the drug is of biological origin there is no involvement of any chemical process

The drug will be a remedy to Plaque Psoriasis for about 1 percent to 2 percent affected population in India.

Use of this drug in Psoriasis affected individual ensures a prolonged remission period of about 25 weeks to 28 weeks. So proves itself efficient against other available drugs for Psoriasis, the use of which gives a remission period only of about 5 weeks to 15 weeks.

How much one need to spend to reach ALZUMAb?

Rs. 7950 for a vial which is actually almost halve the rate compared to other Psoriasis drugs in the market. As discussed above, the longer remission period enhanced by the drug has significant effect on the amount to be spent on the drug.

Authority to Biocon to market this drug in India: Approved by Drugs Controller General of India

Biocon as its next step to market this product globally is in the process of seeking approval from FDA by filing an investigational new drug application.

The drug is expected to be a cure for few other ailments like rheumatoid arthritis, Psoriatic arthritis and multiple sclerosis by its manufacturer and the clinical trials is underway for the same.